Patents by Inventor Lyndon L. Larcom

Lyndon L. Larcom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • UVC rediation therapy for leukemia
    Patent number: 6970740
    Abstract: Leukocytes from leukemia patients have been found to be readily killed by ultra-violet light-C (UVC) radiation. Cells from healthy donors were minimally affected by doses of UVC 10 times higher than those which caused dramatic drops in the metabolism of diseased cells and eventual death. Irradiated cells from leukemia patients and from healthy individuals demonstrated a number of single strand DNA breaks and alkali-labile sites compared to unirradiated control cells. The extent of DNA damage to both healthy and diseased cells is dose dependent. However, the diseased cells demonstrated more extensive DNA fragmentation and an inability to undergo self-repair. The heightened sensitivity to UVC radiation of diseased leukocytes from leukemia patients is used to provide an excorporeal treatment of diseased leukocytes followed by the re-introduction of the treated leukocytes to the patient.
    Type: Grant
    Filed: June 30, 2003
    Date of Patent: November 29, 2005
    Assignee: Clemson University
    Inventors: Lyndon L. Larcom, Amy Tuck, Samuel Smith
  • UVC radiation therapy for leukemia
    Publication number: 20040137418
    Abstract: Leukocytes from leukemia patients have been found to be readily killed by ultra-violet light-C (UVC) radiation. Cells from healthy donors were minimally affected by doses of UVC 10 times higher than those which caused dramatic drops in the metabolism of diseased cells and eventual death.
    Type: Application
    Filed: June 30, 2003
    Publication date: July 15, 2004
    Applicant: Clemson University
    Inventors: Lyndon L. Larcom, Amy Tuck, Samuel Smith
  • UVC radiation therapy for chronic lymphocytic leukemia
    Patent number: 6585676
    Abstract: Lymphocytes from chronic lymphocytic leukemia (CLL) patients have been found to be readily killed by ultra-violet light-C (UVC) radiation. Cells from healthy donors were minimally affected by doses of UVC 10 times higher than those which caused dramatic drops in the metabolism of CLL cells and eventual death. Irradiated cells from CLL patients and from healthy individuals all demonstrated a number of single strand DNA breaks and alkali-labile sites compared to unirradiated control cells. The extent of DNA damage to both healthy and CLL cells is dose dependent. However, the CLL cells demonstrated more extensive DNA fragmentation and an inability to undergo self-repair. The heightened sensitivity to UVC radiation of lymphocytes from CLL patients is used to provide an excorporeal treatment of CLL lymphocytes followed by the re-introduction of the treated lymphocytes to the patient.
    Type: Grant
    Filed: June 12, 2001
    Date of Patent: July 1, 2003
    Assignee: Clemson University
    Inventors: Lyndon L. Larcom, Amy Tuck, Samuel Smith